Form 4: Xilio Therapeutics SVP Reports Equity Transactions

Xilio Therapeutics' SVP of Finance and Accounting, Kevin M. Brennan, reported the acquisition of common stock from RSU conversion and a 'sell to cover' transaction for tax obligations.

Summary

• Kevin M. Brennan, SVP, Finance and Accounting at Xilio Therapeutics, Inc. [XLO], reported transactions under a Rule 10b5-1 trading plan.
• On January 1, 2026, 5,000 shares of common stock were acquired upon the conversion of Restricted Stock Units (RSUs).
• Following this, on January 2, 2026, 1,826 shares of common stock were sold at a price of $0.6432 per share to cover tax withholding obligations related to RSU vesting.
• Brennan's direct beneficial ownership of common stock after these transactions is 6,371 shares.
• A grant of 95,221 stock options (Tranche 3 Options) with an exercise price of $0.841 was reported, effective December 31, 2025, following stockholder approval of the 2025 Stock Incentive Plan.
• These options vest in three equal annual installments over the three-year period beginning on December 31, 2025, contingent on continued service.
• The vesting of a portion of Tranche 3 Options was met on December 31, 2025, based on the percentage of Series B Warrants exercised or cancelled due to Non-Dilutive Capital receipt.
• 10,000 Restricted Stock Units (RSUs) are beneficially owned, granted on January 1, 2024, vesting in four equal annual installments starting January 1, 2025.

Sentiment

Score: 7

Explanation: The filing primarily details routine executive equity compensation transactions, including RSU conversions and a tax-related stock sale under a 10b5-1 plan. The grant of new stock options and the achievement of performance criteria for a portion of these options are positive indicators of executive incentive alignment and potential operational progress, contributing to a slightly positive sentiment.

Positives

• The grant of 95,221 stock options to a key executive (SVP, Finance and Accounting) indicates continued alignment of management incentives with shareholder value.
• Stockholders approved the 2025 Stock Incentive Plan, demonstrating support for the company's long-term incentive strategy.
• Performance criteria for a portion of the Tranche 3 Options were met by December 31, 2025, linked to Series B Warrants and Non-Dilutive Capital, suggesting progress in specific financial or operational goals.

Negatives

• The sale of 1,826 shares at $0.6432 per share, even if for tax purposes, represents a reduction in direct beneficial ownership.
• The stock price of $0.6432 for the 'sell to cover' transaction is relatively low, which could be a concern depending on the company's historical stock performance.

Risks

• The vesting of stock options and RSUs is subject to the reporting person's continued service to the registrant, posing a risk of forfeiture if employment ceases.
• The value of the stock options and RSUs is tied to the future performance of Xilio Therapeutics' common stock, exposing the holder to market price fluctuations.

Future Outlook

The vesting schedule for the granted stock options and RSUs extends several years into the future, indicating a long-term incentive structure for the reporting person, contingent on continued service and potentially future performance criteria related to Series B Warrants and Non-Dilutive Capital.

Management Comments

• The reported sale of shares was an automatic 'sell to cover' transaction executed under a pre-arranged Rule 10b5-1 trading plan, solely to satisfy tax withholding obligations related to RSU vesting.

Industry Context

This Form 4 filing details routine equity compensation transactions for a senior executive in a publicly traded biotechnology company. Such grants of stock options and restricted stock units are standard practice in the biotech industry to attract, retain, and incentivize key talent, aligning their interests with long-term shareholder value. The use of a Rule 10b5-1 plan for tax-related sales is also a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of stock options and restricted stock units (RSUs) as a significant component of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to companies like Moderna, Pfizer, or Amgen, which frequently utilize equity incentives to motivate leadership.
• The adoption of a Rule 10b5-1 trading plan for 'sell to cover' transactions is a widely accepted corporate governance practice, ensuring that executives can manage tax liabilities from equity vesting without concerns of trading on material non-public information, a standard seen in most public companies.
• The multi-year vesting schedule for both options (three years) and RSUs (four years) is consistent with industry norms designed to promote long-term retention and performance, similar to vesting schedules observed at peer biotech firms for executive equity awards.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The grant of stock options and RSUs aligns executive incentives with shareholder value creation. The 'sell to cover' transaction is a routine event for tax purposes and does not necessarily reflect a change in management's confidence.
• **Employees:** The 2025 Stock Incentive Plan provides a framework for equity compensation, potentially benefiting other employees in the future, contributing to retention and motivation.

Next Steps

• Continued vesting of 95,221 stock options in three equal annual installments over the three-year period beginning on December 31, 2025, subject to continued service.
• Continued vesting of 10,000 Restricted Stock Units in four equal annual installments beginning on January 1, 2025, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation and tax-related transactions by a senior executive. While the grant of new options and the meeting of performance criteria are mildly positive for executive alignment, the filing does not contain information significant enough to warrant a change in investment recommendation. It reflects standard corporate governance and compensation practices rather than new strategic or operational developments that would materially alter the company's investment profile. Therefore, a 'hold' recommendation is appropriate, awaiting more substantive operational or financial news.

Keywords

Xilio Therapeutics, XLO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Executive Compensation, Rule 10b5-1, Sell to Cover, Stock Incentive Plan